Bill > HB0390

This bill establishes a clinical study at the Huntsman Mental Health Institute to research the safety and feasibility of psychedelic-assisted therapy for eligible veterans, defined as those with treatment-resistant PTSD, which means PTSD that has not adequately responded to at least one evidence-based treatment. Psychedelic-assisted therapy involves administering a psychedelic drug, such as MDMA or psilocybin, in a controlled setting alongside trauma-informed psychotherapy before and after the drug administration. The study will be funded by legislative appropriations and any gifts or grants received, and it must begin by January 1, 2027, provided sufficient funds are secured. The bill outlines extensive requirements for the study's protocol, including FDA approval, drug handling procedures, safety monitoring, and therapist qualifications, and mandates that the Huntsman Mental Health Institute report on the study's progress and outcomes to the Health and Human Services Interim Committee. Importantly, the section establishing this clinical study is set to be repealed on July 1, 2032, meaning the research and its associated provisions will expire on that date.

Health and Social Services

https://le.utah.gov/~2026/bills/static/HB0390.html